Rapid and Complete Donor Chimerism in Adult Recipients of Unrelated Donor Umbilical Cord Blood Transplantation After Reduced-intensity Conditioning
Overview
Authors
Affiliations
Reduced-intensity conditioning may reduce transplantation-related mortality in high-risk adults undergoing hematopoietic transplantation. We investigated unrelated donor umbilical cord blood (UCB) transplantation after such conditioning in 43 patients (median age, 49.5 years; range, 22-65 years) with a primary end point of donor engraftment. The first 21 patients received busulfan 8 mg/kg, fludarabine 200 mg/m2, and 200 cGy of total body irradiation (Bu/Flu/TBI). Subsequent patients (n = 22) received cyclophosphamide 50 mg/kg, fludarabine 200 mg/m2, and 200 cGy TBI (Cy/Flu/TBI). UCB grafts (93%) were 1-2 HLA antigen-mismatched with the recipient and contained a median cryopreserved cell dose of 3.7 x 107 (range, 1.6 x 107-6.0 x 107) nucleated cells per kilogram of recipient body weight (NC/kg). Graft versus host disease (GVHD) prophylaxis was cyclosporin A to day 180 plus mycophenolate mofetil to day 30. The cumulative incidence of sustained donor engraftment was 76% (95% confidence interval [CI], 56%-96%) for Bu/Flu/TBI recipients and 94% (95% CI, 84%-100%) for Cy/Flu/TBI recipients. The median day of neutrophil recovery (at least 0.5 x 109/L) for engrafting Bu/Flu/TBI recipients was 26 days (range, 12-30 days) and for Cy/Flu/TBI recipients was 9.5 days (range, 5-28 days). Incidence of grades III-IV acute GVHD was 9% (95% CI, 1%-17%), and survival at 1 year was 39% (95% CI, 23%-56%). These data demonstrate that 0-2 antigen mismatched UCB is sufficient to engraft most adults after reduced-intensity conditioning and is associated with a low incidence of severe acute GVHD.
Okada Y, Usui Y, Hayashi H, Nishikubo M, Toubai T, Uchida N Blood Adv. 2024; 8(6):1359-1368.
PMID: 38163321 PMC: 10945135. DOI: 10.1182/bloodadvances.2023011837.
Umbilical Cord Blood Transplantation: Connecting Its Origin to Its Future.
Sanchez-Petitto G, Rezvani K, Daher M, Rafei H, Kebriaei P, Shpall E Stem Cells Transl Med. 2023; 12(2):55-71.
PMID: 36779789 PMC: 9985112. DOI: 10.1093/stcltm/szac086.
Ding J, Fang Y, Zhou R, Gu Y, Du S, Lu Q Cell Transplant. 2022; 31:9636897211070238.
PMID: 35073786 PMC: 8793423. DOI: 10.1177/09636897211070238.
Brunstein C, DeFor T, Fuchs E, Karanes C, McGuirk J, Rezvani A Transplant Cell Ther. 2021; 27(10):879.e1-879.e3.
PMID: 34273598 PMC: 8858593. DOI: 10.1016/j.jtct.2021.07.006.
Microfluidics as efficient technology for the isolation and characterization of stem cells.
Aghlmandi A, Nikshad A, Safaralizadeh R, Warkiani M, Aghebati-Maleki L, Yousefi M EXCLI J. 2021; 20:426-443.
PMID: 33746671 PMC: 7975637. DOI: 10.17179/excli2020-3028.